ERWIN L. GREENBERG is Founder and Chairman Emeritus of Greenberg Gibbons Commercial Corporation, developers of retail shopping centers in the Mid-Atlantic region and nationally based in Owings Mills, Maryland. STEPHANIE COOPER GREENBERG has had careers in banking, investment banking, small business ownership, fundraising and non-profit development in Boston, New Orleans, Washington and Baltimore.
Stephanie Cooper Greenberg is a member of the Board of Trustees at Johns Hopkins Bayview Medical Center as well as serves on several Advisory Boards including the Johns Hopkins Center for Innovative Medicine at Bayview, the Johns Hopkins Children’s Center, Rheumatology Advisory Board and Berman Institute of Bioethics. She is also a member of the board of the Kennedy Krieger Institute and the State of Maryland Cancer Control Board. Erwin and Stephanie Greenberg serve as directors of the Erwin & Stephanie Greenberg Foundation, which focuses its funding initiatives toward human service, education, and medical research.
Recognizing that, despite its prevalence, bladder cancer tends to receive less attention and funding than other cancers, Erwin and Stephanie chose to make a meaningful difference by directing their $15 million gift toward this single area of immense need. The Greenberg’s hope the co-investment with the Johns Hopkins University will help the Institute promote discovery, improve patient care and outcomes, and ultimately drive the global field of bladder cancer research closer to a cure.
DAVID J. McCONKEY, PhD, inaugural director of the Johns Hopkins Greenberg Bladder Cancer Institute and Professor in the Department of Urology at Johns Hopkins Medicine, received his undergraduate degree from Brown University and completed his doctoral thesis work at the Karolinska Institute, Stockholm, Sweden. He performed his postdoctoral research at the Dana-Farber Cancer Institute before joining the faculty at University of Texas M.D. Anderson Cancer Center, where he served as Director of Urological Research from 2008-16. He is co-Principal Investigator of the M.D. Anderson Specialized Program of Research Excellence (SPORE) in Bladder Cancer, which is now in its third continuous cycle of funding from the National Cancer Institute (NCI). He is also Chair for Translational Medicine for the Genitourinary Cancers Committee in the Southwest Oncology Group (SWOG).